MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - GSK PHARMA
ASTRAZENECA PHARMA vs GSK PHARMA - Comparison Results
ASTRAZENECA PHARMA Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
GSK PHARMA 
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
Current Valuations
| ASTRAZENECA PHARMA | GSK PHARMA | ASTRAZENECA PHARMA/ GSK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 63.3 | 45.4 | 139.3% | View Chart |
| P/BV | x | 17.8 | 9.6 | 186.5% | View Chart |
| Dividend Yield | % | 0.0 | 1.7 | - |
Financials
 ASTRAZENECA PHARMA  GSK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
GSK PHARMA Mar-19 |
ASTRAZENECA PHARMA/ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 3,595 | 35.5% | |
| Low | Rs | 883 | 1,253 | 70.4% | |
| Sales per share (Unadj.) | Rs | 228.4 | 184.7 | 123.7% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 26.3 | 39.4% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 29.2 | 55.8% | |
| Dividends per share (Unadj.) | Rs | 0 | 20.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.8 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 126.3 | 78.2% | |
| Shares outstanding (eoy) | m | 25.00 | 169.40 | 14.8% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.7 | 13.1 | 36.0% | |
| Avg P/E ratio | x | 104.2 | 92.2 | 113.1% | |
| P/CF ratio (eoy) | x | 66.4 | 83.1 | 79.9% | |
| Price / Book Value ratio | x | 10.9 | 19.2 | 57.0% | |
| Dividend payout | % | 0 | 76.1 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 410,626 | 6.6% | |
| No. of employees | `000 | 1.4 | 5.0 | 27.3% | |
| Total wages/salary | Rs m | 1,535 | 5,372 | 28.6% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 6,306.7 | 66.8% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 1,083.1 | 104.5% | |
| Avg. net profit/employee | Rs Th | 191.1 | 898.0 | 21.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 31,281 | 18.3% | |
| Other income | Rs m | 123 | 1,023 | 12.0% | |
| Total revenues | Rs m | 5,833 | 32,304 | 18.1% | |
| Gross profit | Rs m | 463 | 6,009 | 7.7% | |
| Depreciation | Rs m | 147 | 486 | 30.3% | |
| Interest | Rs m | 0 | 6 | 0.0% | |
| Profit before tax | Rs m | 438 | 6,540 | 6.7% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 287 | 0.0% | |
| Tax | Rs m | 179 | 2,373 | 7.5% | |
| Profit after tax | Rs m | 259 | 4,454 | 5.8% | |
| Gross profit margin | % | 8.1 | 19.2 | 42.2% | |
| Effective tax rate | % | 40.8 | 36.3 | 112.6% | |
| Net profit margin | % | 4.5 | 14.2 | 31.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 20,061 | 16.0% | |
| Current liabilities | Rs m | 2,070 | 14,543 | 14.2% | |
| Net working cap to sales | % | 20.0 | 17.6 | 113.1% | |
| Current ratio | x | 1.6 | 1.4 | 112.4% | |
| Inventory Days | Days | 72 | 57 | 127.4% | |
| Debtors Days | Days | 35 | 14 | 248.4% | |
| Net fixed assets | Rs m | 790 | 14,343 | 5.5% | |
| Share capital | Rs m | 50 | 1,694 | 3.0% | |
| "Free" reserves | Rs m | 2,419 | 19,704 | 12.3% | |
| Net worth | Rs m | 2,469 | 21,398 | 11.5% | |
| Long term debt | Rs m | 0 | 2 | 0.0% | |
| Total assets | Rs m | 4,605 | 39,113 | 11.8% | |
| Interest coverage | x | NM | 1,091.0 | - | |
| Debt to equity ratio | x | 0 | 0 | 0.0% | |
| Sales to assets ratio | x | 1.2 | 0.8 | 155.0% | |
| Return on assets | % | 5.6 | 11.4 | 49.3% | |
| Return on equity | % | 10.5 | 20.8 | 50.4% | |
| Return on capital | % | 17.7 | 31.9 | 55.6% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 300 | 534 | 56.1% | |
| Fx outflow | Rs m | 2,015 | 7,091 | 28.4% | |
| Net fx | Rs m | -1,715 | -6,557 | 26.2% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 3,994 | 2.2% | |
| From Investments | Rs m | -94 | -1,433 | 6.5% | |
| From Financial Activity | Rs m | NA | -3,584 | 0.0% | |
| Net Cashflow | Rs m | -6 | -1,023 | 0.6% | |
Share Holding
| Indian Promoters | % | 0.0 | 0.0 | - | |
| Foreign collaborators | % | 75.0 | 50.7 | 147.9% | |
| Indian inst/Mut Fund | % | 0.3 | 10.2 | 2.9% | |
| FIIs | % | 15.7 | 23.8 | 66.0% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 15.4 | 59.1% | |
| Shareholders | 12,856 | 102,036 | 12.6% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: PFIZER ABBOTT INDIA FRESENIUS KABI ONCO. WYETH LTD TORRENT PHARMA
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Opens Flat; Realty and Metal Stocks Lag(09:30 am)
Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.1% while the Hang Seng is flat.
Related Views on News
EDELWEISS FINANCIAL Plunges by 5%; BSE 500 Index Down 0.1% (Market Updates)
Aug 21, 2019 | Updated on Aug 21, 2019EDELWEISS FINANCIAL share price has plunged by 5% and its current market price is Rs 120. The BSE 500 is down by 0.1%. The top gainers in the BSE 500 Index are JAGRAN PRAKASHAN (up 5.6%) and MAHINDRA CIE AUTO. (up 4.4%). The top losers are EDELWEISS FINANCIAL (down 5.4%) and ASTRAZENECA PHARMA (down 6.0%).
ASTRAZENECA PHARMA Plunges by 6%; BSE HEALTHCARE Index Down 0.1% (Market Updates)
Aug 21, 2019 | Updated on Aug 21, 2019ASTRAZENECA PHARMA share price has plunged by 6% and its current market price is Rs 1,757. The BSE HEALTHCARE is down by 0.1%. The top gainers in the BSE HEALTHCARE Index are BIOCON (up 2.7%) and ALEMBIC PHARMA (up 2.2%). The top losers is ASTRAZENECA PHARMA (down 6.0%)..
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)
Jul 24, 2019 | Updated on Jul 24, 2019For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
More Views on NewsMost Popular
The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)
Aug 8, 2019This debt-free, well-managed company is all set to soar.
This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)
Aug 12, 2019My experience at the recent AGM of this smallcap company which has financials of any FMCG major.
Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)
Aug 9, 2019Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.
Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)
Aug 12, 2019Only These Smallcaps Will Give Historic Returns in the Future.
Qatar is Rearing Cows...this is Good News for India
Aug 9, 2019Qatar has turned around after the Saudi embargo. This is good news for India.
MoreASTRAZENECA PHARMA SHARE PRICE
Aug 21, 2019 10:45 AM
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA - LUPIN COMPARISON
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.